Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

This Tuesday, the Health Ministry will begin training medical teams ahead of a historic campaign to protect all Israeli ...

Health secretary Robert F. Kennedy Jr.’s decision to discontinue funding of the development of messenger RNA vaccines is not ...

Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the peak of the season, a number they hope will increase as more women are ...

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-pe ...

The study found the program was more than 85% effective in reducing infant hospitalizations, emergency-room consultations and ...

Q2 2025 Management View Paul Hudson, CEO, reported "another strong quarter with double-digit sales growth," attributing the performance to innovation, new product launches, and vaccines, with ...

Sanofi Q2 sales rose 10.1% at constant currency, led by Dupixent and ALTUVIIIO. EPS missed estimates; 2025 sales guidance was ...

Investing.com -- Sanofi (EPA: SASY) shares fell more than 2% on Thursday after the pharmaceutical and healthcare company ...